We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Global Immunoassay Market to Reach USD 19.76 Billion by 2025 with Increased Use in Oncology

By LabMedica International staff writers
Posted on 29 Aug 2019
Print article
Image: The global immunoassay market is projected to reach almost USD 20 billion by 2025 (Photo courtesy of iStock).
Image: The global immunoassay market is projected to reach almost USD 20 billion by 2025 (Photo courtesy of iStock).
The global immunoassay market is projected to grow at a CAGR of 5.9% from 2019 to reach USD 19.76 billion by 2025, driven by increasing incidences of chronic and infectious diseases, growing use of immunoassay in oncology, rise in drug and alcohol testing, and technological advancements in immunoassay. The emerging markets and increasing epidemic potentials offer significant growth opportunities for players operating in the market. However, the limitations of immunoassay and development of alternative technologies are expected to hinder the adoption of immunoassay products.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Based on product, the immunoassay kits and reagents segment is expected to account for the largest share of the global immunoassay market in 2019 due to the increasing number of immunoassay tests being performed across the world driving the recurrent purchase of kits and reagents. Within the immunoassay kits and reagents segment, ELISpot kits and reagents are projected to grow at the highest CAGR during the forecast period, led by the rising incidences of chronic diseases across the world, growing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot assay kits and analyzers.

On the basis of application, the infectious diseases segment is expected to hold the largest share of the global immunoassay market in 2019, mainly due to rising incidences of infectious diseases and growing adoption of immunoassay diagnostics in infectious diseases. However, the oncology segment is expected to record the highest CAGR during the forecast period on the back of the rising prevalence of cancer, increasing focus on tumor market development, technological advancements, and growing awareness about cancer.

Geographically, North America dominated the global immunoassay market with the largest share in 2018, mainly due to the rising incidence of infectious diseases, growing prevalence of cancer, and increasing healthcare expenditure, along with the presence of major immunoassay players and highly developed healthcare infrastructure in the region.

Related Links:
Research and Markets

Print article


Molecular Diagnostics

view channel
Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)

Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children

MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria. MiRNAs comprise a class of about 20 n... Read more


view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.